SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 7/13/20 EyePoint Pharmaceuticals, Inc. 8-K:5,9 7/13/20 2:63K ActiveDisclosure/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 22K 2: EX-99.1 Miscellaneous Exhibit HTML 18K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): July 13, 2020
EyePoint Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware |
|
|
26-2774444 |
|
(State or Other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
480 Pleasant Street
(Address of Principal Executive Offices, and Zip Code)
(617) 926-5000
Registrant’s Telephone Number, Including Area Code
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
☐ |
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, par value $0.001 |
|
EYPT |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
|
(b) Director Resignation.
On July 13, 2020, Dr. Jay Duker resigned from the Board of Directors (the “Board”) of EyePoint Pharmaceuticals, Inc. (the “Company”), effective immediately. Dr. Duker has resigned from the Board in order to join the Company as the Company’s Chief Strategic Scientific Officer. |
Also on July 13, 2020, the Company issued a press release announcing the appointment of Dr. Duker as the Company’s Chief Strategic Scientific Officer. A copy of the Company’s press release relating to Dr. Duker’s appointment is attached hereto as Exhibit 99.1.
Item 9.01. |
Financial Statements and Exhibits. |
(d) Exhibits.
|
|
|
Exhibit No. |
|
Description |
|
|
|
99.1 |
|
Press Release of Eyepoint Pharmaceuticals, Inc. dated July 13, 2020. |
|
|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
EyePoint Pharmaceuticals, Inc. |
||
|
|
|||
Date: July 13, 2020 |
|
By: |
|
/s/ Nancy Lurker |
|
|
Name: |
|
|
|
|
Title |
|
President and Chief Executive Officer |
This ‘8-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on / For Period end: | 7/13/20 | None on these Dates | ||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/12/21 EyePoint Pharmaceuticals, Inc. S-3 3:260K Donnelley … Solutions/FA 2/02/21 EyePoint Pharmaceuticals, Inc. 424B5 1:493K Donnelley … Solutions/FA 2/01/21 EyePoint Pharmaceuticals, Inc. 424B5 1:496K Donnelley … Solutions/FA 1/15/21 EyePoint Pharmaceuticals, Inc. S-3 4:662K Donnelley … Solutions/FA 11/06/20 EyePoint Pharmaceuticals, Inc. S-8 11/06/20 3:88K Donnelley … Solutions/FA 8/05/20 EyePoint Pharmaceuticals, Inc. 424B5 1:536K Donnelley … Solutions/FA |